BIOMAT Database Logo BIOMAT Database Logo

Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants. 1992

P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
University Hospital Geneva, Department of Infectious Diseases, Switzerland.

The in-vitro activity of five new fluoroquinolones, WIN 57273, sparfloxacin, fleroxacin, temafloxacin and ciprofloxacin was determined against 543 recent clinical isolates and eight quinolone resistant strains derived by mutation and their five parent strains. WIN 57273 was the most active compound against Gram-positive bacteria, sparfloxacin had a broad spectrum which was similar to that of ciprofloxacin. Ciprofloxacin showed the greatest activity against Gram-negative bacteria. Temafloxacin showing some activity against Gram-positive organisms and Acinetobacter spp. Fleroxacin was the least active compound studied. Compared to wild type parent strains, the mutated strains produced the following results. In Enterobacter cloacae OmpF deficiency increased the MICs of all quinolones by 8-32-fold. In Pseudomonas aeruginosa OmpF deficiency had a limited effect, Omp D2 deficiency combined with an increased lipopolysaccharide content produced greater resistance, i.e. 4-16-fold; mutations in gyrase were associated with variously increased MICs, depending on the strain and compound tested.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D042462 4-Quinolones QUINOLONES containing a 4-oxo (a carbonyl in the para position to the nitrogen). They inhibit the A subunit of DNA GYRASE and are used as antimicrobials. Second generation 4-quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine at the 6-position. 4-Oxoquinoline,4-Quinolinone,4-Quinolone,4-Oxoquinolines,4-Quinolinones,4 Oxoquinoline,4 Oxoquinolines,4 Quinolinone,4 Quinolinones,4 Quinolone,4 Quinolones

Related Publications

P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia.
March 2000, The Journal of antimicrobial chemotherapy,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
February 1986, Antimicrobial agents and chemotherapy,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
[Activity of new quinolones against clinical isolates of Corynebacterium species].
September 2000, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
April 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
Comparative in vitro antimicrobial activity of tigecycline against clinical isolates of vancomycin-resistant enterococcus.
January 2009, Indian journal of medical microbiology,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
June 1987, Pathologie-biologie,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
January 1985, Scandinavian journal of infectious diseases,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia.
December 1999, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
Activity of new quinolones against ciprofloxacin-resistant staphylococci.
August 1991, Antimicrobial agents and chemotherapy,
P Rohner, and M Peebo, and D P Lew, and R Auckenthaler, and J C Pechère
The in vitro activity of ceftazidime against resistant clinical isolates.
January 1983, Infection,
Copied contents to your clipboard!